Merck Revives Spat With Teva Over Fosamax
In a long-simmering patent dispute over blockbuster osteoporosis drug Fosamax, Merck & Co. is striking back at Israeli generic maker Teva Pharmaceuticals, saying Teva garnered a Federal Circuit victory last year...To view the full article, register now.
Already a subscriber? Click here to view full article